Invesco WilderHill Clean Energy ETF vs Vaxcyte Inc. Common Stock — how do they compare? Invesco WilderHill Clean Energy ETF trades at $25.75 (market cap $315.85M), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 33.3× Invesco WilderHill Clean Energy ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 47 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| PBW | PCVX | |
|---|---|---|
Market Cap | $315.85M | $10.51B |
Volume | 452,833 | 2,644,694 |
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $73.82 |
52-Week Low | $25.77 | $40.32 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
The Invesco WilderHill Clean Energy ETF (PBW) trades at $27.33, down 0.33% on the day, with a bearish technical signal driven by moving averages. Key financial ratios such as P/E and P/S are not applicable for this ETF. Recent news highlights institutional selling, with IFP Advisors cutting its stake by 96.3% in Q2 2026 (SEC filing, September 18, 2026).
The outlook is cautious due to technical weakness and institutional outflows. Opportunities lie in the clean energy theme amid global investment, but risks include high volatility and concentrated portfolio strategy. The ETF's performance is tied to sector sentiment rather than traditional corporate fundamentals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →